VCEL

57.5201.27%
HM

Heidi M. Hagen

Independent Director

Ms. Heidi M. Hagen serves as Board Member of A-Alpha Bio, Inc. She is a Member of Scientific Advisory Board at Lykan BioScience, LLC from September 2022. She served as Member of Scientific Advisory Board of RoslinCT since August 2022. She served as Chief Technical Officer at Sonoma Biotherapeutics, Inc. from November 2021 to 2023. She had been Director of Ziopharm Oncology, Inc. since June 13, 2019, until November 02, 2021 and served as Interim Chief Executive Officer and Principal Executive Officer since February 25, 2021 until August 30, 2021. She serves as an Independent Director at Obsidian Therapeutics, Inc. since November 2021. Ms. Hagen has extensive experience in operations management and commercializing innovative technologies, including many years in the cell and gene therapy industry. Currently, Ms. Hagen is Chief Technical Officer of Sonoma Biotherapeutics, a privately held company leading the development of adoptive Treg cell therapies for autoimmune and inflammatory diseases. She also serves on the Board of Directors for cell therapy company Vericel. She served as Lead Independent Director at ZIOPHARM Oncology, Inc. since January 14, 2021, until February 25, 2021. She is Co-Founder of Vineti Inc. and was its Advisor since October 2015 until February 2021 and had been its Chief Strategy Officer since October 2015 until 2020. She has been Strategic Advisor of NAVAN Technologies, Inc. Ms. Hagen is the Chief Operating Officer and co-Founder of Vitruvian Networks. Ms. Hagen has held the position of a biotechnology and pharmaceutical operations and technology consultant with HH Consulting Limited Liability Company since October 2012. She served as Research Fellow connected w/ Univ of Wash at Quinton Instrument Company since August 1990 until August 1993. She served as Senior Manager of Supply Operations/Project Management/Research Assoc at Immunex Inc since August 1993 until September 2002. Prior to co-founding Vitruvian Networks, she served as Global Chief Operating Officer of Sotio LLC (Sotio a.s.) from March 2013 to April 2014. She served as an Interim CCO at ZappRx since January 2015 until June 2015. Ms. Hagen served as Senior Vice President of Operations at Dendreon Corporation from October 2002 to May 2012. She has been an Operations Executive in the Biotechnology industry for many years. Prior to Dendreon, Ms. Hagen employed at Immunex Corporation for many years, where she held several positions in drug development and supply chain and operations management. She has an extensive and proven track record in leading operations and commercializing innovative technologies ranging from recombinant protein/device combinations to the first active immune cell therapy, Provenge. She serves as an Independent Director of Vericel Corporation since August 23, 2013 and serves on the Board of Directors of Lykan Biosciences LLC, a privately held contract manufacturing company, since June 2019. Ms. Hagen holds a B.S. in Cell and Molecular Biology from 1987 to 1990, M.S. in Bioengineering from 1991 to 1993 and an MBA from the University of Washington from 1999 until 2001.

Positions